Poliomyelitis
Poliomyelitis (polio) is an acute human enteroviral infectious disease caused by poliovirus serotypes 1, 2, and 3 (species Enterovirus C, family Picornaviridae) that replicates in the pharynx and gastrointestinal tract and can invade spinal and bulbar motor neurons to cause irreversible acute flaccid paralysis.
Poliomyelitis (commonly termed polio, from the Ancient Greek polios, "grey," and myelos, "marrow," referring to the grey matter of the spinal cord) is an acute human viral infectious disease caused by any of the three antigenically distinct serotypes of poliovirus (PV1, PV2, and PV3; classified within the species Enterovirus C, genus Enterovirus, family Picornaviridae). Transmitted exclusively among humans (with no non-human animal reservoir) via the fecal-oral and oral-oral routes, poliovirus infects the oropharyngeal and intestinal lymphoid mucosa via the human poliovirus receptor (PVR / CD155). While 70% to 75% of infections remain completely asymptomatic and another ~24% produce a transient minor febrile illness (abortive poliomyelitis), in approximately 1 in 200 to 1 in 1,000 infections (depending on serotype) viremic virions cross into the central nervous system and selectively lyse alpha motor neurons in the anterior horn of the spinal cord and brainstem motor nuclei, resulting in permanent, asymmetric acute flaccid paralysis (AFP). Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, global immunization with Sabin oral polio vaccine (OPV) and Salk inactivated polio vaccine (IPV) has reduced wild poliovirus incidence by >99.9% and eradicated wild serotypes 2 (certified 2015) and 3 (certified 2019).
Virion Structure, CD155 Receptor Entry, and Neurovirulence
Non-Enveloped Pseudo-T=3 Icosahedral Capsid and (+)ssRNA Genome
Resolved at 2.9 Å atomic resolution via X-ray crystallography by James M. Hogle, Marie Chow, and David Baltimore in 1985, the poliovirus virion is a non-enveloped icosahedral particle (~30 nm in diameter) exhibiting pseudo-T = 3 symmetry. The protein capsid is assembled from 60 protomers, each composed of four structural viral proteins (VP1, VP2, VP3, which fold into eight-stranded antiparallel β-barrels on the outer surface, and the internal myristoylated protein VP4). Surrounding the five-fold icosahedral axes of symmetry is a deep surface depression—the "canyon"—into which the human receptor CD155 (PVR) inserts, triggering ejection of a stabilizing lipid pocket factor from VP1, externalization of VP4 and the N-terminus of VP1 to form a membrane pore, and release of the genomic RNA into the host cytoplasm. Because it lacks a lipid envelope, the poliovirus capsid resists gastric acid (surviving pH < 2.0), bile salts, ether, ethanol, and non-ionic detergents, persisting for weeks in sewage and surface water until inactivated by heat (>55 °C), formaldehyde, free chlorine, or ultraviolet irradiation.
The viral genome is a single-stranded, positive-sense RNA virus molecule of ~7,440 nucleotides covalently linked at its 5′ terminus to the 22-amino-acid viral protein VPg (3B) (rather than a 7-methylguanosine cap) and terminated by a 3′ poly(A) tail. The 742-nucleotide 5′ untranslated region (5′ UTR) folds into six cloverleaf and stem-loop domains (Domains I–VI), where Domains II–VI form a Type I Internal Ribosome Entry Site (IRES) that recruits host 40S ribosomal subunits directly without cap-dependent scanning. Simultaneously, viral protease 2Apro cleaves host eukaryotic initiation factor eIF4G, shutting off cap-dependent host protein translation while translating the viral genome into a single ~247-kDa polyprotein cleaved by viral cysteine proteases 2Apro and 3Cpro/3CDpro into structural (P1: VP4-VP2-VP3-VP1) and non-structural replication proteins (P2: 2A-2B-2C; P3: 3A-3B[VPg]-3Cpro-3Dpol, where 3Dpol is the error-prone RNA-dependent RNA polymerase).
Enteric Amplification, CD155 Tropism, and Anterior Horn Motor Neuron Lysis
Human infection proceeds through three anatomical compartments:
- Mucosal Entry and Lymphoid Replication: Ingested virions bind CD155 (nectin-like molecule 5, Necl-5)—an immunoglobulin-superfamily transmembrane glycoprotein restricted to humans and Old World primates—on M cells and follicular dendritic cells in the tonsils and ileal Peyer's patches, shedding high viral titers in pharyngeal secretions for 1–2 weeks and in feces for 3 to 6 weeks.
- Viremia: Drainage into deep cervical and mesenteric lymph nodes seeds a primary minor viremia into the bloodstream; if neutralizing IgG/IgA antibodies are absent, secondary replication in reticuloendothelial tissues produces a sustained major viremia.
- CNS Invasion and Anterior Horn Pathology: Poliovirus enters the central nervous system either by crossing the blood-brain barrier across CD155-expressing capillary endothelium or via retrograde axonal transport along peripheral motor nerves from skeletal muscle neuromuscular junctions. Because spinal anterior horn alpha motor neurons, cranial nerve nuclei (IX, X, XI, XII in the medulla oblongata), and precentral motor cortex Betz cells express high surface densities of CD155, viral replication inside these post-mitotic neurons triggers chromatolysis, microglial neuronophagia, and permanent denervation of the corresponding skeletal muscle motor units.
| Clinical / Epidemiological Parameter | Serotype 1 (PV1) | Serotype 2 (PV2) | Serotype 3 (PV3) |
|---|---|---|---|
| Paralysis-to-Infection Ratio | ~1 : 200 infections (most neurovirulent) | ~1 : 2,000 infections | ~1 : 1,000 infections |
| Wild-Type (WPV) Eradication Status | Endemic only in Afghanistan & Pakistan | Certified eradicated Sept 2015 (last case Aligarh, India, Oct 1999) | Certified eradicated Oct 2019 (last case Yobe, Nigeria, Nov 2012) |
| Sabin OPV Attenuation Gatekeeper (5′ UTR Domain V) | G480A (plus VP1/VP3/3Dpol mutations) | A481G (plus VP1 Ile143Thr; reverts rapidly) | U472C (plus VP3 Phe91Ser; lowest VAPP threshold) |
| Circulating VDPV (cVDPV) Threshold | >1.0% (>9 nt) VP1 divergence from Sabin 1 | >0.6% (≥6 nt) VP1 divergence from Sabin 2 (>90% of cVDPV outbreaks) | >1.0% (>9 nt) VP1 divergence from Sabin 3 |
Salk (IPV) vs. Sabin (OPV) Vaccines and Novel OPV2 (nOPV2) Engineering
Complementarity of Systemic IgG (IPV) and Intestinal Secretory IgA (OPV)
Polio control relies on two complementary vaccine platforms developed in the 1950s:
- Inactivated Polio Vaccine (IPV, Jonas Salk, 1955): Contains wild-type or Sabin strains of all three serotypes inactivated with formalin and administered intramuscularly or intradermally. IPV induces high titers of circulating serum IgG that completely prevent viremic entry into the central nervous system (100% protection against paralysis after 2–3 doses) and carries zero risk of vaccine-associated paralysis or genetic reversion. However, in individuals never previously exposed to live intestinal infection, parenteral IPV elicits weak intestinal mucosal secretory IgA (sIgA); consequently, IPV-vaccinated individuals can still be asymptomatically infected in the gut and shed wild or vaccine-derived poliovirus in feces, allowing silent community transmission Detected in wastewater environmental surveillance.
- Live-Attenuated Oral Polio Vaccine (OPV, Albert Sabin, 1961): Administered orally as two drops, Sabin strains replicate in the gut to elicit both serum IgG and robust intestinal secretory IgA, blocking fecal viral shedding and interrupting fecal-oral transmission in low-sanitation settings.
The Sabin Domain V Reversion Problem and Rational Design of nOPV2
Because the attenuation of all three Sabin OPV strains depends critically on single point mutations within Domain V of the 5′ UTR IRES (A480G in Sabin 1, A481G in Sabin 2, and U472C in Sabin 3) that weaken base-pairing and impair translation in human neurons, replication of Sabin OPV in the human gut rapidly selects for back-mutation (reversion) at these single nucleotides within days of vaccination. Rarely (~1 in 2.7 million first OPV doses), reversion causes Vaccine-Associated Paralytic Poliomyelitis (VAPP) in the recipient or a close contact. More dangerously, when Sabin vaccine virus circulates person-to-person for 12 to 18 months in under-immunized communities (particularly following the global April 2016 withdrawal of Sabin type 2 from routine trivalent OPV), it accumulates >0.6%–1.0% nucleotide divergence in the 900-nt VP1 capsid region and frequently recombines with other human Enterovirus C strains to become a circulating Vaccine-Derived Poliovirus (cVDPV) with wild-type neurovirulence and transmissibility.
To eliminate Sabin 2 reversion while preserving oral intestinal mucosal immunity, Raul Andino, Andrew Macadam, and an international consortium engineered the novel Oral Polio Vaccine type 2 (nOPV2) through five rational genetic modifications to the Sabin 2 genome (Yeh et al., 2020):
- Stabilization of 5′ UTR Domain V (S15 DomV): Replaced weak U–G wobble pairs in Domain V entirely with canonical C–G Watson-Crick base pairs, so that any single point mutation destabilizes rather than restores the neurovirulent stem-loop structure (requiring multiple simultaneous mutations to revert).
- Relocation of the cre (cis-acting replication element): Moved the essential 2C cre hairpin into the 5′ UTR spacer upstream of Domain V, preventing the virus from replacing its stabilized 5′ UTR via 5′ homologous recombination with co-infecting Enterovirus C strains.
- High-Fidelity and Low-Recombination 3Dpol Mutations (HiFi + Rec1): Introduced two amino acid substitutions into the 3Dpol RNA-dependent RNA polymerase—Asp53Asn (D53N) to increase replication fidelity and Lys38Arg (K38R) to reduce homologous RNA recombination rates—alongside codon deoptimization of the capsid region.
Recent Events
In 2022 and 2023, following the rapid clinical and field rollout of the genetically stabilized novel Oral Polio Vaccine type 2 (nOPV2) under WHO Emergency Use Listing across sub-Saharan Africa and the Middle East, genomic surveillance confirmed an ~80% reduction in the risk of seeding new circulating vaccine-derived poliovirus type 2 (cVDPV2) emergences compared with monovalent Sabin OPV2, while parallel molecular engineering extended the stabilized 5′ UTR Domain V and high-fidelity 3Dpol design to nOPV1 and nOPV3 vaccine candidates [5] [6].
In December 2023, the World Health Organization granted full prequalification to nOPV2—making it the first vaccine to transition from WHO Emergency Use Listing to full prequalification based on field genetic stability and clinical safety data—following the interruption of the imported wild poliovirus type 1 (WPV1) outbreak in Malawi and Mozambique and the containment of global WPV1 transmission to 12 paralytic cases across eastern Afghanistan and Pakistan [5] [7].
In 2024, Global Polio Eradication Initiative surveillance documented a resurgence of endemic WPV1 to more than 90 paralytic cases across Pakistan (Balochistan, Sindh, and Khyber Pakhtunkhwa) and southern and eastern Afghanistan amid population displacement and security barriers to house-to-house immunization, while an emergency two-round nOPV2 vaccination campaign in the Gaza Strip immunized over 560,000 children following the detection of cVDPV2 in wastewater and a paralytic case in July–September 2024, pushing cumulative global nOPV2 administration past 1 billion doses across more than 35 countries [7] [6].
Frequently Asked Questions
Why can't Injectable Inactivated Polio Vaccine (IPV) alone stop poliovirus circulation in settings with poor sanitation?
Injectable Salk IPV stimulates high levels of circulating IgG antibodies in the bloodstream, which completely block poliovirus from crossing from the blood into the spinal cord and therefore protect the vaccinated individual 100% against paralysis. However, unless a person has previously experienced a live gut infection or received oral polio vaccine, intramuscular IPV produces very little secretory IgA (sIgA) on the mucosal surface of the small intestine. If an IPV-vaccinated person ingests poliovirus in contaminated water, the virus can still multiply harmlessly in their intestinal tract and be shed in their stool for weeks, allowing silent fecal-oral transmission through the community and sewage system until high coverage with oral polio vaccine (OPV or nOPV2) induces mucosal gut immunity.
How did the designers of nOPV2 prevent the vaccine virus from mutating back into a paralyzing form?
Classic Sabin OPV2 relies on a single nucleotide change (A481G) in a folded RNA hairpin (Domain V of the 5′ UTR) that weakens the structure; a single back-mutation during gut replication restores the strong wild-type hairpin and neurovirulence within days. In nOPV2, virologists replaced all the weak U–G wobble pairs in Domain V with strong C–G base pairs at the desired attenuated stability, so any single point mutation only weakens the hairpin further. To prevent the virus from swapping out this engineered 5′ UTR by recombining with other human enteroviruses in the gut, they also moved the essential cre replication element to the 5′ end of the genome and mutated the 3Dpol polymerase (K38R and D53N) to suppress recombination and copying errors.
What is Post-Polio Syndrome (PPS), and is it caused by reactivation of the virus?
Post-Polio Syndrome (PPS) is a slowly progressive neuromuscular condition affecting 25% to 40% of polio survivors 15 to 40 years after recovery from their initial acute paralytic infection, characterized by new muscle weakness, fatigue, and atrophy in previously affected or seemingly unaffected limbs. PPS is not caused by persistent or reactivated poliovirus (patients are not contagious). Instead, during recovery from the original acute attack, surviving spinal motor neurons sprouted extra axonal branches to adopt orphaned muscle fibers left behind by lysed neighboring neurons, creating giant motor units up to 5–8 times normal size; after decades of metabolic overuse and normal age-related motor neuron attrition, these distal terminal axonal sprouts degenerate.
References
- Hogle, J. M., Chow, M., & Baltimore, D. (Sep 27, 1985). Three-dimensional structure of poliovirus at 2.9 Å resolution. Science, 229(4720), 1358–1365. https://doi.org/10.1126/science.2994218
- Mendelsohn, C. L., Wimmer, E., & Racaniello, V. R. (1989). Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell, 56(5), 855–865. https://doi.org/10.1016/0092-8674(89)90690-9
- Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (Oct 1, 2005). Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annual Review of Microbiology, 59, 587–635. https://doi.org/10.1146/annurev.micro.58.030603.123625
- Yeh, M. T., Bujaki, E., Dolan, P. T., Smith, M., Wahid, R., Konz, J., Weiner, A. J., Tibbetts, C., Tsetsarkin, K., Chumakov, K., & Macadam, A. (2020). Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host & Microbe, 27(5), 736–751.e8. https://doi.org/10.1016/j.chom.2020.04.003
- Macklin, G. R., Peak, C., Eisenhawer, M., Kurji, F., Mach, O., Konz, J.,... & Bandyopadhyay, A. S. (2023). Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience. Vaccine. https://doi.org/10.1016/j.vaccine.2022.02.050
- Yeh, M. T., Smith, M., Carlyle, S., Konopka-Anstadt, J. L., Burns, C. C., Konz, J., Andino, R., & Macadam, A. (Jul 6, 2023). Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3. Nature, 619(7968), 135–142. https://doi.org/10.1038/s41586-023-06212-3
- World Health Organization (WHO) & Global Polio Eradication Initiative. (2024). Persistence of wild poliovirus type 1 and global surveillance of circulating vaccine-derived polioviruses. Weekly Epidemiological Record, 99(21), 275–290. https://polioeradication.org/